|
Objective: To investigate patients with type 2 diabetes in C-reactive protein (CRP) and diabetic retinopathy (DR) relationship. Research on C-reactive protein levels in Healthy control group, Non-diabetic retinopathy group,Ⅰ,Ⅱ,Ⅲ,ⅣDR Group whether the period of inter-group differences exist, differences in changes in the law, as well as C-reactive protein are able to type 2 diabetes and diabetic retinopathy, development risk factors, to a certain extent in patients with type 2 diabetes the risk of diabetic retinopathy, diabetic retinopathy whether the severity of the prediction value.Methods: Materials and methods: Blood samples were included in the study came from the next morning after the venous blood. Subjects were collected after 10 hours fasting 4ml venous blood samples, non-anticoagulant tube in 37℃water bath 30 minutes after centrifugation for 10 minutes at low temperature (3000rPm), separation of serum are sealed in packaging to preserve the reserve-20℃.1.Determination of two hours of fasting and postprandial plasma glucose using glucose oxidase method, serum lipids, renal function, liver function test application produced by Byer automatic biochemical analyzer measured by our biochemical laboratory personnel. 2.Body mass index (BMI): that is, BMI= weight (kg)/height~2 (m~2).Weight measurements to fasting, after voiding, and the deduction of shoes and jackets go weight: height measurement requirements to take off their shoes and hats height when standing (weight and height measurements are used to measure the same measuring instruments). 3.C-reactive protein levels using enzyme-linked immunosorbent assay (ELISA) determination of operation according to kit instructions. Approved within the 1.7% difference -3.9%, approved between -5.1% to 2.8%, so using the same batch, DG3022 applications for enzyme-linked immunosorbent assay absorbance detector (OD) detected.Specific operation was taken by the hospital biochemistry laboratory room staff in the completion of the immune.4. Glycosylated hemoglobin (HbAlc): the use of micro-column method. HbAlc measured by BIO-RAD kit provided by (micro-column test), the port from the resin micro-column (containing the weak acid ion exchange resin -phosphate buffer), eluate (lotion a: phosphate buffersolution pH 7.0, lotion b: phosphate buffer pH 6.7), as well as the composition of hemolysin, HbAlc standard provided by BIO-RAD. Spectrophotometer: Shimadzu UV730. Determination of the steps: (1) All reagents and samples werefrozen at 25℃temperature pre-heating tank 20 min;(2) First anticoagulant EDTA-2Na add 0.1 ml of whole blood 1.5 ml of hemolysin produced hemoglobin solution; (3) This solution add 0.1ml pre-blending and precipitation of micro-column resin well; (4) First eluate a1.5 ml pre-washed, and then use lotion b-eluting hemoglobin HbAlc liquid diluent with the same period last year one color (wavelength 505 nm),each determined to do high and low standards of the a;(5) Calculation of the total hemoglobin HbA1c percentage HbA1c (%) = (HbA1C eluate absorbance/ absorbance of hemoglobin diluent)×hemoglobin concentration (g/L). Into the group of standards (in accordance with the 1999 WHO diagnostic criteria for diabetes mellitus): [1] Diabetes diagnostic criteria:①Diabetes with typical symptoms,any time blood glucose≥11..1mmol/l (200mg/dl);②No typical symptoms, only eight hours of fasting The fasting plasma glucose≥7.0 mmol/l(126mg/dl);③No typical symptoms, oral glucose tolerance test 2 hours plasma glucose≥11.1 mmol/1 (200mg/dl); any of the above-mentioned three criteria to reach a diagnosis of diabetes. [2] Diagnostic criteria for diabetic retinopathy by fundus lesions can be divided into six, belonging to two categories:Ⅰperiod: micro-aneurysms or there is and there is a small bleeding points; PhaseⅡ:there is yellow and white of "hard exudates" or there is bleeding and plaque;Ⅲperiod: there is a white "soft exudative" or there is bleeding and plaque;Ⅳperiod: there is fundus neovascularization and vitreous hemorrhage;Ⅴperiod: fundus there is proliferation of new blood vessels and fiber;Ⅵperiod: the fundus, and there is neovascularization fiber proliferation, complicated retinal detachment.Ⅰ-Ⅲover a period of background (simple) retinopathy,Ⅳ-Ⅵproliferative period (proliferative) retinopathy.Results: Healthy control group (A group) C-reactive protein, HbAlc levels, respectively (1.23±0.38)mg/L, (4.3±0.8)%, non-diabetic retinopathy group (B Group) C-reactive protein, HbAlc levels were (2.14±1.18) mg / L, (8.5±1.5)%, were significantly different from diabetic retinopathy group (C group) were (2.94±1.91) mg / L, (9.8±2.1)%, A Group group B were significantly different (P <0.01), A group of C group were significantly different (P <0.01), B Group C group were significantly different (P<0.05).Lesions and serum C-reactive protein levels, HbA1c levels: According to the principle of random sampling, the patient in terms of gender difference was not statistically significant, note the occurrence of diabetic microangiopathy is not the impact of gender. DataⅠ,Ⅱ,Ⅲ,Ⅳdiabetic retinopathy group of C-reactive protein levels, HbAlc were significantly higher than the normal control group, there was a significant difference; four diabetic retinopathy between groups C-reactive protein levels have significantly differences (P<0.05),the existence of statistical significance, C-reactive protein levels and diabetic retinopathy level was positively correlated, and C-reactive protein level and the level of HbAlc was positively correlated line (P<0.05), the existence of statistical significance.Conclusion:C-reactive protein levels in non-diabetic retinopathy group at a relatively gradual increase in the healthy control group showed that type 2 diabetes are probably cytokine-mediated inflammatory response. C-reactive protein levels in non-diabetic retinopathy group,Ⅰ,Ⅱ,Ⅲ,Ⅳdiabetic retinopathy group was gradually increased, indicating that their are probably type 2 diabetes and diabetic retinopathy, development of risk factors, to some extent, type 2 diabetic patients the risk of diabetic retinopathy, diabetic retinopathy with the severity of the prediction value.
|